MIRA PHARMACEUTICALS, INC. 8-K

What Happened MIRA PHARMACEUTICALS, INC. (filed 8-K on 2026-05-13) announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences reporting preclinical in vitro and zebrafish in vivo results for its investigational oral drug candidate SKNY-1 (being evaluated for obesity and nicotine addiction). The paper, titled “SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity,” is available online at MDPI (https://www.mdpi.com/1422-0067/27/10/4321). The Company emphasized these results are from preclinical zebrafish and in vitro studies; SKNY-1 is not FDA-approved and human safety and efficacy have not been established.

Key Details

• Publication: peer-reviewed article in International Journal of Molecular Sciences (link above).
• Weight effect: oral SKNY-1 produced dose-dependent reductions in body weight over six days, with ~30% reduction from baseline in the higher-dose group.
• Pharmacology: showed differential engagement of CB1 signaling pathways, partial agonist activity at CB2, and selective in vitro inhibition of MAO-B vs MAO-A.
• Additional preclinical findings: normalization of total cholesterol and LDL, increased HDL, reduced hepatic triglycerides, modulation of leptin/ghrelin gene expression, and reduced compulsive feeding and nicotine-seeking behaviors.

Why It Matters For investors, the publication provides independent, peer-reviewed preclinical evidence supporting SKNY-1’s proposed mechanisms (cannabinoid receptor modulation and MAO-B activity) and early efficacy signals on weight, metabolic markers and reward-related behaviors. These results can help validate the science behind the program and may support future clinical development plans. However, these are early-stage, non-clinical findings in zebrafish and in vitro systems — they do not demonstrate safety or efficacy in humans and do not guarantee clinical or regulatory success.